evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

18 questions · 18 findings · 7 reviews · Neuromuscular

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 1 · 5.6%Very low 5 · 27.8%Low 3 · 16.7%Moderate 3 · 16.7%High 6 · 33.3%

Corticosteroids vs placebo

Adverse effects requiring withdrawal/discontinuation of study medication · people with nerve damage (6 to 24 months' duration) in leprosy

Corticosteroids showed no clear difference in adverse events Assessed as adverse events requiring withdrawal of… compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroids vs placebo

Adverse events Assessed as: occurrence of one or more major adverse events requiring withdrawal of treatment · people with nerve damage (< 6 months' duration) in leprosy

Corticosteroids showed no clear difference in adverse events Assessed as: occurrence of one or more major adverse… compared with placebo (moderate certainty).

1 finding from 1 review

Corticosteroids vs placebo compared

Serious adverse events (dichotomous data) ‐ suspected or probable pneumonia · critically ill patients

Corticosteroids showed no clear difference in serious adverse events (dichotomous data) ‐ suspected or probable… compared with placebo compared (high certainty).

1 finding from 1 review

Antivirals plus corticosteroids vs corticosteroids plus placebo or no treatment

Adverse events № of participants: 656 (2 RCTs) · Bell's palsy

It is very uncertain whether antivirals plus corticosteroids changes adverse events № of participants: 656 (2 RCTs) compared with corticosteroids plus placebo or no treatment (AS versus OS) (very low certainty).

1 finding from 1 review

Corticosteroids vs control

Adverse events: hypertension · patients with Guillain‐Barré syndrome

Corticosteroid leads to lower adverse events ‐ hypertension compared with control (high certainty).

1 finding from 1 review

Brain‐derived neurotrophic factor vs placebo

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether brain‐derived neurotrophic factor changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Cerebrospinal fluid filtration vs plasma exchange

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether cerebrospinal fluid filtration changes participants with 1 or more serious adverse events compared with plasma exchange (very low certainty).

1 finding from 1 review

Eculizumab vs placebo

Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset

Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Interferon beta‐1a vs placebo

Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome

It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).

1 finding from 1 review

Corticosteroids vs control

Adverse events ‐ Diabetes mellitus requiring insulin · patients with Guillain‐Barré syndrome

Corticosteroid leads to higher adverse events ‐ diabetes mellitus requiring insulin compared with control (high certainty).

1 finding from 1 review

Intervention not reported

Serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)

It is very uncertain whether the intervention changes serious adverse eventsClinical manifestation and laboratory… (very low certainty).

1 finding from 1 review

Intervention not reported

Non‐serious adverse eventsClinical manifestation and laboratory examination · people with acute herpes zoster (within 7 days of onset of rash)

The intervention showed no clear difference in non‐serious adverse eventsClinical manifestation and laboratory… (low certainty).

1 finding from 1 review